SB's Factive not approved

Published: 3-Feb-2001


SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.

You may also like